Company profile

Stemcentrx

Stemcentrx raised approximately $500M, including a $250M Series G in Aug 2015 backed by Fidelity, Founders Fund and Artis Ventures, and prior Series B and other rounds. Founded in 2008, Stemcentrx developed antibody-drug conjugates targeting cancer stem cells and companion diagnostics; multiple clinical candidates entered human trials with objective responses in several tumor types. Funding supported extensive R&D, IND filings, and early clinical development. The company was later acquired its scientific programs influenced oncology pipelines and partnerships in ADC development.

Back to profiles

Quick facts

Total funding: $500M
Founded: 2008

Notable investors

Fidelity
Founders Fund
Artis Ventures

Reach buyers like Stemcentrx on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Stemcentrx
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Stemcentrx.

The 14-day trial ships every feature, no card required.

Start free →